Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 March 2023 | Story Alicia Pienaar
Prof Mathys Labuschagne
Prof Mathys Labuschagne is the Head of the Clinical Simulation and Skills Unit within the School of Biomedical Sciences in the Faculty of Health Sciences

The Dean of the Faculty of Health Sciences, Prof Gert van Zyl, invites you to the inaugural lecture of Prof Mathys Labuschagne, Head of the Clinical Simulation and Skills Unit within the School of Biomedical Sciences in the Faculty of Health Sciences. 

Subject: Clinical Simulation: Quo Vadis? 
Venue:  Auditorium, Equitas Building, Bloemfontein Campus 
Date: 8 March 2023 
Time: 17:30 

RSVP on or before Friday 3 March 2023

Light refreshments will be served after the inaugural lecture.


About Prof M Labuschagne

Prof Mathys Labuschagne is the Head of the Clinical Simulation and Skills Unit within the School of Biomedical Sciences in the Faculty of Health Sciences at the University of the Free State. He completed his MB ChB degree and qualified as an ophthalmologist in 2006.

He developed an interest in health professions education and obtained a PhD in Health Professions Education in June 2012. The title of his thesis was: Clinical Simulation to enhance undergraduate medical education and training at the University of the Free State.

Prof Labuschagne was appointed Head of the Clinical Simulation and Skills Unit at the University of the Free State. The facility is utilised for undergraduate and postgraduate clinical simulation training, as well as interprofessional training and research. He has a special interest in simulation as training tool, precision skills training, and mastery of learning and simulation as tool to prepare students for interprofessional education and collaborative practice.

Prof Labuschagne is part of a multi-institutional consortium that developed the MySkills Medic app. It is a clinical procedural skills application aimed at graduating medical students, interns, and community-service doctors. He was appointed as a member of the Ophthalmology Foundation Education Simulation Subcommittee (affiliate of the International Council of Ophthalmology) tasked with developing a white paper to guide simulation training for ophthalmologists. He is involved in postgraduate supervision for master’s and PhD students in HPE.


News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept